Feature Article

New hope for interstitial lung disease

Feature Article

New hope for interstitial lung disease

ALAN K.Y. TEOH, TAMERA J. CORTE

Figures

© MHEIM3011/ISTOCKPHOTO.COM MODEL USED FOR ILLUSTRATIVE PURPOSES ONLY
© MHEIM3011/ISTOCKPHOTO.COM MODEL USED FOR ILLUSTRATIVE PURPOSES ONLY

Abstract

Interstitial lung disease (ILD) comprises a large heterogenous group of disorders causing varying degrees of lung damage. Treatment options have historically been limited and are associated with significantly increased morbidity and mortality. This review summarises new advances in the diagnostic and management pathways of ILD.

Key Points

  • Interstitial lung diseases (ILDs) are a heterogenous group of conditions that cause lung parenchymal inflammation and fibrosis.
  • Early recognition can be difficult but should be prioritised to allow rapid assessment with additional investigations.
  • A multidisciplinary meeting discussion is key to establishing a diagnosis of ILD and, hence, an early referral to an ILD outpatient service or a local respiratory physician is critical.
  • A comprehensive management strategy for patients with ILD requires a multidisciplinary team approach, utilising both pharmacological therapies and nonpharmacological measures.